Targeted Therapy on the Screen: Do We Hit the Target?

A phase II trial, investigating whether the antidiabetic drug metformin could reduce hypoxia in cervical cancer, used imaging to preselect patients and test the biological hypothesis behind the drug effect. This trial design would be of importance for the implementation of targeted treatment in the clinic.

Automated summary

A phase II trial investigated the potential of using metformin to reduce hypoxia in cervical cancer. The study used imaging to select patients and test the biological hypothesis behind the drug effect, which is of importance for targeted treatment in the clinic.